SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Indo US Bio-Tech Ltd

BSE: 541304 NSE: INDOUS ISIN: INE250Z01010
  |   Sector:  Agriculture & Allied activities   |   Industry:  Agriculture

Snapshot

Q.1 Which industry/sub-sector does Indo US Bio-Tech Ltd belong to?
Indo US Bio-Tech Ltd belongs to the Agriculture & Allied activities sector, operating specifically within the Agriculture segment.
Q.2 Is Indo US Bio-Tech Ltd a good quality company?
Indo US Bio-Tech Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Indo US Bio-Tech Ltd undervalued or overvalued?
Indo US Bio-Tech Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 5-year
Historic Median
Price to Earnings 13.72 25.10
Price to Book 2.27 4.03
Price to Sales 1.73 3.35
EV to EBITDA 12.45 20.96
Q.4 Is Indo US Bio-Tech Ltd a good buy now?
Indo US Bio-Tech Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd revenue growth is 42.6% for FY-2025, which is above its 5-year CAGR of 21.17%, indicating faster growth.

Q.2 Gross Profit margin of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Gross profit margin which is the profit after deduction of direct costs, is 17% for FY-2025, which is above its 5-year median of 13.2%, indicating increasing margins.

Q.3 Operating Profit Margin of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 18.24% for FY-2025, which is above its 5-year median of 14.84% indicating increasing margins.

Q.4 Net Profit Margin of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Net Profit Margin is 15.67% for FY-2025, is above its 5-year median of 11.73%, indicating increasing margins.
Current Level 5-year
Historic Median
Gross Profit Margin (%) 17 13.2
Operating Profit Margin (%) 18.24 14.84
Net Profit Margin (%) 15.67 11.73

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Return on Asset is 17.98%, which is above its 5-year historical median of 11.67%, indicating improved asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Return on capital employed is 21.15% for FY-2025, which is above its 5-year historical median of 15.86%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q.7 Return on Equity (ROE) of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Return on equity is 23.03% for FY-2025, which is above its 5-year historical median of 17.34%, indicating the business is making better use of its shareholders capital.

Q.8 Cash conversion cycle of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Cash conversion cycle is 265 days, in line with its 5-year historical median of 265 days, indicating stable working capital management. However, you need to compare this with its peers in the industry.
Current Level 5-year
Historic Median
Asset Turnover (x) 1.15 1.02
ROE (%) 23.03 17.34
ROCE (%) 21.15 15.86
Cash Conversion Cycle 265 days 265 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Debt-to-Equity ratio is 0.19, which is above the industry average of 0.13, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd Debt to cash flow from operations is 10.45, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Indo US Bio-Tech Ltd?

Q.1 Promoter shareholding and pledge status of Indo US Bio-Tech Ltd?
Promoters hold 68.29% of the Indo US Bio-Tech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Indo US Bio-Tech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Indo US Bio-Tech Ltd vs industry peers?
Indo US Bio-Tech Ltd revenue CAGR is 21.17%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Profit Metrics
Current Level 5-year
Industry Median
Revenue Growth (%) 42.6 0
Gross Profit Growth (%) 80 15.2
Operating Profit Growth (%) 72.7 21.2
Net Profit Growth (%) 100 8.5
Operating Efficiency
Current Level 5-year
Industry Median
Asset Turnover (x) 1.15 0.53
ROE (%) 23.03 7.6
ROCE (%) 21.15 8.57
Cash Conversion Cycle (days) 265.16 73

Valuation & price assessment

Q.1 Stock return of Indo US Bio-Tech Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 45.98% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR		 - 46% -1% -32.2%
Q.2 Valuation ratios of Indo US Bio-Tech Ltd vs historical?
The current P/E ratio of 13.72 is lower than its historical median of 25.10, indicating that the stock is trading below its historical average valuation.
Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?
Valuation Ratios Current 5-year
Historic Median		 5-year
Industry Median
Price to Earnings 13.72 25.10 20.70
Price to Book 2.27 4.03 1.93
Price to Sales 1.73 3.35 1.89
EV to EBITDA 12.45 20.96 13.08

Check more companies

1. Kaveri Seed
2. Venkys India
3. AVT Natural Prod
4. Bombay Super Hybrid
5. Regaal Resources
6. Freshara Agro Export
7. Mangalam Global Ent
8. Kotyark Industries
9. Sheetal Universal
10. Nath Bio-Genes

Check trending companies

1. Reliance Power Ltd.
2. Bharat Heavy Electricals Ltd.
3. CESC Ltd.
4. Welspun Corp Ltd.
5. Sagility Ltd.
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×